Market Intelligence, Clinical Progress, and High-Purity Reagents for Glutaminolysis-Targeted Cancer Therapeutics.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for KGA/GLS drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KGA/GLS Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Active tetrameric conformation. |
View GLS Products |
| Gene Delivery | KGA/GLS Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression validation. |
View GLS Products |
| Benchmark Ab | Anti-KGA/GLS Recombinant Antibody Recombinant positive control for western blot, IHC, and IP. |
View GLS Products |
| Validator | KGA/GLS siRNA Set For knockdown verification and target specificity assays. |
View GLS Products |
| Related Target A | SLC1A5 (ASCT2) Primary glutamine transporter acting upstream of GLS; critical for synergistic combination therapy screening. |
View SLC1A5 Products |
| Related Target B | GLUD1 (GDH) Downstream enzyme converting glutamate to alpha-ketoglutarate; essential for metabolic flux analysis. |
View GLUD1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Maintaining active tetrameric state for allosteric inhibitor screening | Recombinant GLS proteins optimized for oligomeric stability and sequence-verified for correct folding. |
| Screening against drug-resistant mutations in the allosteric pocket | Custom mutant recombinant proteins (e.g., K320A, Y394F) designed for selectivity and resistance profiling. |
| Lack of Controls | Clinical-grade benchmark antibodies and validated positive controls included in the workflow. |
| False Positives | Sequence-verified siRNA sets included for target-specific knockdown validation in cell-based assays. |
Live KGA/GLS R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KGA/GLS therapeutics is intensifying, with major players shifting focus from traditional monotherapies to combination regimens. As first-generation allosteric inhibitors like Telaglenastat (CB-839) navigate clinical trials, the next wave of R&D is targeting drug-resistant mutations and metabolic bypass pathways. Precision medicine approaches are increasingly utilizing GLS inhibition in combination with EGFR inhibitors, immunotherapies, or chemotherapy to overcome adaptive resistance in glutamine-addicted tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Allosteric) | Calithera Biosciences, Incyte | Solid Tumors (TNBC, NSCLC), Hematological Malignancies | Enzymatic inhibition assays (Need highly active tetrameric WT & mutant proteins) |
| Combination Therapy | AstraZeneca, Merck | Keap1/Nrf2-mutant NSCLC, Refractory Tumors | Synergy assays & pathway validation (Need stable cell lines via Lentivirus) |
| RNA Therapeutics | Academic Spin-offs | Metabolic reprogramming in oncology | Target knockdown validation (Need sequence-verified siRNA sets) |